USE OF chemically modified US PRODUCTS IN THE DRAFT ISLAND

摘要

This invention refers to chemically modified heparin for use in the treatment of sickle cell disease,with a counter-agent activity II less than 10 IU/mg, a counter-agent activity Xa less than 10 IU/mg and an average molecular weight (MB) between approximately 6,5 and 9,5 kDA.